… We therefore designed a prospective multicenter phase II study to address the impact of …
in clinically staged T3 or low-lying T2 rectal cancer patients who had a major clinical response …

… In conclusion, this phase II study demonstrates that a trimodal therapy regimen with acceptable
toxicity can be applied safely in patients with advanced rectal carcinomas. HT was used …

… This study used a randomized, phase II, parallel design. The incompletion rate of TME for
the rectal cancer … In conclusion, robot-assisted surgery for mid- to low-lying rectal cancer was …

… Preoperative chemoradiotherapy is feasible in rectal cancer patients and does not induce
unacceptable toxicity. Its potential value should be demonstrated throughout clinical trials. …

… In recent years our study group designed clinical trials to improve the efficacy in terms of
local recurrence and prevention of metastases in rectal cancer. In the R02 study [26] the …

… ), and OS in metastatic colorectal cancer 27,28 and survival … poor prognosis rectal cancer in
a single-arm phase II trial (EXPERT… (EGFR) therapy in metastatic colorectal cancer, 31,32 the …

… In this multicenter, prospective, randomized, controlled trial of patients with stage II or III
rectal cancer at or below 12 cm above the anal verge, all of whom underwent neoadjuvant …

… One hundred ten patients with T3/T4 or N+ rectal cancer were entered onto the trial in 11
investigator sites and received preoperative RT (50.4 Gy in 28 fractions). Capecitabine was …

… This phase II prospective study was conducted to evaluate … rectal cancer based on the
results of our previous pilot study showing the safety and feasibility of this procedure. In this study, …

… phase II study investigates the efficacy of total neoadjuvant therapy (TNT) and selective
non-operative management (NOM) in LARC. Patients with MRI-staged Stage II or III rectal cancer …